<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34669264</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-1124</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of diabetes investigation</Title><ISOAbbreviation>J Diabetes Investig</ISOAbbreviation></Journal><ArticleTitle>Immunohistochemical detection of enteroviruses in pancreatic tissues of patients with type&#x2009;1 diabetes using a polyclonal antibody against 2A&#x2009;protease of Coxsackievirus.</ArticleTitle><Pagination><StartPage>435</StartPage><EndPage>442</EndPage><MedlinePgn>435-442</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jdi.13700</ELocationID><Abstract><AbstractText Label="AIMS/INTRODUCTION" NlmCategory="OBJECTIVE">The need for antiserum for immunohistochemical (IHC) detection of enterovirus (EV) in formaldehyde-fixed and paraffin-embedded samples is increasing. The gold standard monoclonal antibody (clone 5D8/1) against EV-envelope protein (VP1) was proven to cross-react with other proteins. Another candidate marker of EV proteins is 2A&#x2009;protease (2A<sup>pro</sup> ), which is encoded by the EV gene and translated by the host cells during EV replication, and participates processing proproteins to viral capsid proteins.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We raised polyclonal antiserum by immunizing a rabbit with an 18-mer peptide of Coxsackievirus&#x2009;B1 (CVB1)-2A<sup>pro</sup> , and examined the specificity and sensitivity for EV on formaldehyde-fixed and paraffin-embedded tissue samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Enzyme-linked immunosorbent assay study showed a high titer of antibody for 18-mer peptide of CVB1-2A<sup>pro</sup> , cross-reacting with CVB3-2A<sup>pro</sup> peptide. IHC showed that antiserum against 2A<sup>pro</sup> reacted with CVB1-infected and VP1-positive Vero cells. Confocal laser scanning microscopy showed that antigen stained by the 2A<sup>pro</sup> antibody located in the same cell with VP1 stained by 5D8/1. IHC using 2A<sup>pro</sup> antiserum showed dense staining in the islets of EV-associated fulminant type&#x2009;1 diabetes pancreas and that located in the same cell stained positive for VP1 (5D8/1). Specificity of 2A<sup>pro</sup> antiserum by IHC staining was confirmed by negative 2A<sup>pro</sup> in 14 VP1-negative non-diabetes control pancreases.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study provides a new polyclonal antiserum against CVB1-2A<sup>pro</sup> , which might be useful for IHC of EV-infected human tissues stored as archive of formaldehyde-fixed and paraffin-embedded tissue samples.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jimbo</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Immunology and Molecular Medicine, Okinaka Memorial Institute for Medical Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Tetsuro</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4364-2527</Identifier><AffiliationInfo><Affiliation>Division of Immunology and Molecular Medicine, Okinaka Memorial Institute for Medical Research, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeshita</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mine</LastName><ForeName>Keiichiro</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9759-4148</Identifier><AffiliationInfo><Affiliation>Division of Metabolism and Endocrinology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagafuchi</LastName><ForeName>Seiho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Metabolism and Endocrinology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukui</LastName><ForeName>Tomoyasu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yagihashi</LastName><ForeName>Soroku</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4255-774X</Identifier><AffiliationInfo><Affiliation>Department of Exploratory Medicine on Nature, Life, and Man, Toho University School of Medicine, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>15K09406</GrantID><Agency>Japan Society for Promotion of Science KAKENHI</Agency><Country/></Grant><Grant><GrantID>21K08541</GrantID><Agency>Japan Society for Promotion of Science KAKENHI</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Diabetes Investig</MedlineTA><NlmUniqueID>101520702</NlmUniqueID><ISSNLinking>2040-1116</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010179" MajorTopicYN="N">Pancreas</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2A protease</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Polyclonal antiserum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34669264</ArticleId><ArticleId IdType="pmc">PMC8902398</ArticleId><ArticleId IdType="doi">10.1111/jdi.13700</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alidjinou EK, San&#xe9; F, Engelmann I, et&#xa0;al. Enterovirus persistence as a mechanism in the pathogenesis of type 1 diabetes. Discov Med 2014; 18: 273&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">25425468</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Svedin E, Kapell S, et&#xa0;al. Enteroviral proteases: structure, host interactions and pathogenicity. Rev Med Virol 2016; 26: 251&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169145</ArticleId><ArticleId IdType="pubmed">27145174</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser LJ, Langereis MA, Rabouw HH, et&#xa0;al. Essential role of enterovirus 2A protease in counteracting stress granule formation and the induction of type I interferon. J Virol 2019; 93: e00222&#x2013;e319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6498061</ArticleId><ArticleId IdType="pubmed">30867299</ArticleId></ArticleIdList></Reference><Reference><Citation>Badorff C, Lee G&#x2010;H, Lamphear BJ, et&#xa0;al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5: 320&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">10086389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim B&#x2010;K, Peter AK, Xiong D, et&#xa0;al. Inhibition of Coxsackievirus&#x2010;associated dystrophin cleavage prevents cardiomyopathy. J Clin Investig 2013; 123: 5146&#x2013;5151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859391</ArticleId><ArticleId IdType="pubmed">24200690</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Svedin E, Kapell S, et&#xa0;al. New Coxsackievirus 2Apro and 3Cpro protease antibodies for virus detection and discovery of pathogenic mechanisms. J Virol Methods 2018; 255: 29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">29425680</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Dhayal S, et&#xa0;al. Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. Diabetologia 2014; 57: 392&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">24190581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson SF, Korsgren S, Pont&#xe9;n F, et&#xa0;al. Detection of enterovirus in the islet cells of patients with type 1 diabetes: what do we learn from immunohistochemistry? Diabetologia 2014; 57: 645&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">24352376</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Dhayal S, et&#xa0;al. Detection of enterovirus in the islet cells of patients with type 1 diabetes: what do we learn from immunohistochemistry? Reply to Hansson SF, Korsgren S, Pont&#xe9;n F et&#xa0;al. [letter]. Diabetologia 2014; 57: 647&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">24429580</ArticleId></ArticleIdList></Reference><Reference><Citation>Aida K, Nishida Y, Tanaka S, et&#xa0;al. RIG&#x2010;I&#x2010; and MDA5&#x2010;initiated innate immunity linked with adaptive immunity accelerates beta&#x2010;cell death in fulminant type 1 diabetes. Diabetes 2011; 60: 884&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046849</ArticleId><ArticleId IdType="pubmed">21289206</ArticleId></ArticleIdList></Reference><Reference><Citation>Takita M, Jimbo E, Fukui T, et&#xa0;al. Unique inflammatory changes in exocrine and endocrine pancreas in enterovirus&#x2010;induced fulminant type 1 diabetes. J Clin Endocrinol Metab 2019; 104: 4282&#x2013;4294.</Citation><ArticleIdList><ArticleId IdType="pubmed">31112279</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S, Nishida Y, Aida K, et&#xa0;al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta&#x2010;cell failure in fulminant type 1 diabetes. Diabetes 2009; 58: 2285&#x2013;2291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750208</ArticleId><ArticleId IdType="pubmed">19641142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Tanaka S, Aida K. Unique pathological changes in the pancreas of fulminant type 1 diabetes. Diabetol Int 2020; 11: 323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538509</ArticleId><ArticleId IdType="pubmed">33088638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez&#x2010;Calvo T. Enterovirus infection and type 1 diabetes: unraveling the crime scene. Clin Exp Immunol 2019; 195: 15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6300647</ArticleId><ArticleId IdType="pubmed">30307605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekoua MP, Dechaumes A, Sane F, et&#xa0;al. Enteroviral pathogenesis of type 1 diabetes: the role of natural killer cells. Microorganisms 2020; 8: 989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409131</ArticleId><ArticleId IdType="pubmed">32630332</ArticleId></ArticleIdList></Reference><Reference><Citation>Domsgen E, Lind K, Kong L, et&#xa0;al. An IFIH1 gene polymorphism associated with risk for autoimmunity regulates canonical antiviral defense pathways in Coxsackievirus infected human pancreatic islets. Sci Rep 2016; 6: 39378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5175199</ArticleId><ArticleId IdType="pubmed">28000722</ArticleId></ArticleIdList></Reference><Reference><Citation>Geravandi S, Liu M, Maedler K. Enteroviruses and T1D: is it the virus, the genes or both which cause T1D. Microorganisms 2020; 8: 1017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409303</ArticleId><ArticleId IdType="pubmed">32650582</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte BM, Lanke KHW, Piganelli JD, et&#xa0;al. Cytokine and chemokine production by human pancreatic islets upon enterovirus infection. Diabetes 2012; 61: 2030&#x2013;2036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402326</ArticleId><ArticleId IdType="pubmed">22596052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercalli A, Lampasona V, Klingel K, et&#xa0;al. No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia 2012; 55: 2479&#x2013;2488.</Citation><ArticleIdList><ArticleId IdType="pubmed">22684312</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse N, Paroni F, Richardson SJ, et&#xa0;al. Detection and localization of viral infection in the pancreas of patients with type 1 diabetes using short fluorescently&#x2010;labelled oligonucleotide probes. Oncotarget 2017; 8: 12620&#x2013;12636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5355040</ArticleId><ArticleId IdType="pubmed">28147344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascoli CA, Aggeler B. Overlooked benefits of using polyclonal antibodies. Biotechniques 2018; 65: 127&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">30089399</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Langereis MA, Lork M, et&#xa0;al. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J Virol 2014; 88: 3369&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957915</ArticleId><ArticleId IdType="pubmed">24390337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Xi X, Lei X, et&#xa0;al. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti&#x2010;viral type I interferon responses. PLoS Pathog 2013; 9: e1003231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605153</ArticleId><ArticleId IdType="pubmed">23555247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamphear BJ, Yan R, Yang F, et&#xa0;al. Mapping the cleavage site in protein synthesis initiation factor eIF&#x2010;4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem 1993; 268: 19200&#x2013;19203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8396129</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum SI, Tse HM. Innate Viral sensor MDA5 and Coxsackievirus interplay in type 1 diabetes development. Microorganisms 2020; 8: 993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409145</ArticleId><ArticleId IdType="pubmed">32635205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>